{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T01:57:34Z","timestamp":1767664654638,"version":"3.37.3"},"reference-count":48,"publisher":"BMJ","license":[{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the effects of four drug (quadruple) versus three drug (triple) combination antiretroviral therapies in treatment naive people with HIV, and explore the implications of existing trials for clinical practice and research.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Systematic review and meta-analysis of randomised controlled trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Data sources<\/jats:title><jats:p>PubMed, EMBASE, CENTRAL, Web of Science, and the Cumulative Index to Nursing and Allied Health Literature from March 2001 to December 2016 (updated search in PubMed and EMBASE up to June 2018); and reference lists of eligible studies and related reviews.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study selection<\/jats:title><jats:p>Randomised controlled trials comparing quadruple with triple combination antiretroviral therapies in treatment naive people with HIV and evaluating at least one effectiveness or safety outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Review methods<\/jats:title><jats:p>Outcomes of interest included undetectable HIV-1 RNA, CD4 T cell count, virological failure, new AIDS defining events, death, and severe adverse effects. Random effects meta-analyses were conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twelve trials (including 4251 people with HIV) were eligible. Quadruple and triple combination antiretroviral therapies had similar effects on all relevant effectiveness and safety outcomes, with no point estimates favouring quadruple therapy. With the triple therapy as the reference group, the risk ratio was 0.99 (95% confidence interval 0.93 to 1.05) for undetectable HIV-1 RNA, 1.00 (0.90 to 1.11) for virological failure, 1.17 (0.84 to 1.63) for new AIDS defining events, 1.23 (0.74 to 2.05) for death, and 1.09 (0.89 to 1.33) for severe adverse effects. The mean difference in CD4 T cell count increase between the two groups was \u221219.55 cells\/\u03bcL (\u221243.02 to 3.92). In general, the results were similar, regardless of the specific regimens of combination antiretroviral therapies, and were robust in all subgroup and sensitivity analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this study, effects of quadruple combination antiretroviral therapy were not better than triple combination antiretroviral therapy in treatment naive people with HIV. This finding lends support to current guidelines recommending the triple regimen as first line treatment. Further trials on this topic should be conducted only when new research is justified by adequate systematic reviews of the existing evidence. However, this study cannot exclude the possibility that quadruple cART would be better than triple cART when new classes of antiretroviral drugs are made available.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmj.l4179","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T14:49:03Z","timestamp":1562597343000},"page":"l4179","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.1136","author":[{"given":"Qi","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aoshuang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huachun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Ingle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret T","family":"May","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2386-2431","authenticated-orcid":false,"given":"Zuyao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinling","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,7,8]]},"reference":[{"key":"key20190709000441_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32152-9"},{"key":"key20190709000441_ref2","unstructured":"World Health Organization. Summary of the global HIV epidemic (2017). https:\/\/www.who.int\/hiv\/data\/en\/ Accessed 05 Dec 2018."},{"key":"key20190709000441_ref3","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit150"},{"key":"key20190709000441_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61113-7"},{"key":"key20190709000441_ref5","doi-asserted-by":"publisher","DOI":"10.1177\/0956462414525769"},{"key":"key20190709000441_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60936-1"},{"key":"key20190709000441_ref7","doi-asserted-by":"publisher","DOI":"10.1177\/0956462414553826"},{"key":"key20190709000441_ref8","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12421"},{"key":"key20190709000441_ref9","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000298"},{"key":"key20190709000441_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2014.06.001"},{"key":"key20190709000441_ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7340.757"},{"key":"key20190709000441_ref12","doi-asserted-by":"publisher","DOI":"10.1086\/377311"},{"key":"key20190709000441_ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005381"},{"key":"key20190709000441_ref14","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach.","author":"World Health Organization","year":"2016","edition":"2nd ed"},{"key":"key20190709000441_ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.8722"},{"volume-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV.","year":"2017","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","key":"key20190709000441_ref16"},{"key":"key20190709000441_ref17","unstructured":"European AIDS Clinical Society. Guidelines. Version 9.0. Oct 2017. www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html Accessed 05 Dec 2018."},{"key":"key20190709000441_ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i5440"},{"key":"key20190709000441_ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.7.769"},{"key":"key20190709000441_ref20","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh515"},{"volume-title":"Cochrane handbook for systematic review of interventions.","year":"2011","author":"Higgins","key":"key20190709000441_ref21"},{"key":"key20190709000441_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.006"},{"key":"key20190709000441_ref23","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199901140-00002"},{"key":"key20190709000441_ref24","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh029"},{"key":"key20190709000441_ref25","doi-asserted-by":"publisher","DOI":"10.1086\/648079"},{"key":"key20190709000441_ref26","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2016.1261073"},{"key":"key20190709000441_ref27","doi-asserted-by":"publisher","DOI":"10.1179\/1945577115Y.0000000004"},{"key":"key20190709000441_ref28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"volume-title":"Cochrane handbook for systematic review of interventions.","year":"2011","author":"Higgins","key":"key20190709000441_ref29"},{"key":"key20190709000441_ref30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"volume-title":"Cochrane handbook for systematic review of interventions.","year":"2011","author":"Higgins","key":"key20190709000441_ref31"},{"volume-title":"Cochrane handbook for systematic review of interventions.","year":"2011","author":"Higgins","key":"key20190709000441_ref32"},{"key":"key20190709000441_ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69074-0"},{"key":"key20190709000441_ref34","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01662-12"},{"key":"key20190709000441_ref35","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1177\/135965350300800611","article-title":"A randomized trial comparing initial HAART regimens of nelfinavir\/nevirapine and ritonavir\/saquinavir in combination with two nucleoside reverse transcriptase inhibitors","volume":"8","author":"Kirk","year":"2003","journal-title":"Antivir Ther"},{"key":"key20190709000441_ref36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/135965350601100106","article-title":"An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy","volume":"11","author":"Moyle","year":"2006","journal-title":"Antivir Ther"},{"key":"key20190709000441_ref37","doi-asserted-by":"publisher","DOI":"10.1258\/095646205774988082"},{"key":"key20190709000441_ref38","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000066"},{"key":"key20190709000441_ref39","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(14)70027-X"},{"key":"key20190709000441_ref40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15997-7"},{"key":"key20190709000441_ref41","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001786"},{"key":"key20190709000441_ref42","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2015.0130"},{"key":"key20190709000441_ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30091-1"},{"key":"key20190709000441_ref44","doi-asserted-by":"publisher","DOI":"10.1086\/378301"},{"key":"key20190709000441_ref45","doi-asserted-by":"publisher","DOI":"10.2174\/187152611795589663"},{"key":"key20190709000441_ref46","unstructured":"ClinicalTrial.gov. Antiretroviral therapy for acute and chronic HIV infection (NCT00796263) 2018 https:\/\/www.clinicaltrials.gov\/ct2\/history\/NCT00796263?V_12=View#StudyPageTop."},{"key":"key20190709000441_ref47","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000111"},{"key":"key20190709000441_ref48","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S2055-6640(20)30482-9","article-title":"Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification","volume":"1","author":"Ananworanich","year":"2015","journal-title":"J Virus Erad"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.l4179","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.l4179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T05:36:16Z","timestamp":1663911376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.l4179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,8]]},"references-count":48,"alternative-id":["10.1136\/bmj.l4179"],"URL":"https:\/\/doi.org\/10.1136\/bmj.l4179","relation":{},"ISSN":["0959-8138","1756-1833"],"issn-type":[{"type":"print","value":"0959-8138"},{"type":"electronic","value":"1756-1833"}],"subject":[],"published":{"date-parts":[[2019,7,8]]}}}